Kogenate® FS: Antihemophilic factor rFVIII-FS

Jeanne Lusher; Meera Chitlur

doi:10.1586/14750708.3.6.699

Kogenate® FS: Antihemophilic factor rFVIII-FS

Jeanne Lusher, Meera Chitlur

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Characterization of the factor VIII (FVIII gene and expression of factor VIII through recombinant technology paved the way for the availability of recombinant factor VIII (rFVIII) for intravenous infusion, a significant breakthrough in the treatment of hemophilia A. Kogenate® FS(rFVIII-FS) is a native, full-length factor VIII molecule, produced from a baby hamster kidney cell line, purified and formulated without the addition of albumin, and stabilized with sucrose. Licensed in the USA and the EU in 2000, the hemostatic efficacy and safety (low rate of adverse events, viral safety and low incidence of inhibitors) have been consistently demonstrated through clinical trials and postmarketing studies. Accumulated evidence supports the use of rFVIII-FS for on-demand and prophylaxis treatment regimens, continuous infusion for surgeries or severe bleeding episodes, and immune tolerance induction for treatment of persistent inhibitors.

Original language	English
Pages (from-to)	699-708
Number of pages	10
Journal	Therapy
Volume	3
Issue number	6
DOIs	https://doi.org/10.1586/14750708.3.6.699
State	Published - Nov 2006

Keywords

Factor VIII
Hemophilia A
Kogenate® FS
Recombinant factor VIII
Sucrose-formulated

Access to Document

10.1586/14750708.3.6.699

Cite this

@article{432ba935c6764ee99f701a1d67378257,

title = "Kogenate{\textregistered} FS: Antihemophilic factor rFVIII-FS",

abstract = "Characterization of the factor VIII (FVIII gene and expression of factor VIII through recombinant technology paved the way for the availability of recombinant factor VIII (rFVIII) for intravenous infusion, a significant breakthrough in the treatment of hemophilia A. Kogenate{\textregistered} FS(rFVIII-FS) is a native, full-length factor VIII molecule, produced from a baby hamster kidney cell line, purified and formulated without the addition of albumin, and stabilized with sucrose. Licensed in the USA and the EU in 2000, the hemostatic efficacy and safety (low rate of adverse events, viral safety and low incidence of inhibitors) have been consistently demonstrated through clinical trials and postmarketing studies. Accumulated evidence supports the use of rFVIII-FS for on-demand and prophylaxis treatment regimens, continuous infusion for surgeries or severe bleeding episodes, and immune tolerance induction for treatment of persistent inhibitors.",

keywords = "Factor VIII, Hemophilia A, Kogenate{\textregistered} FS, Recombinant factor VIII, Sucrose-formulated",

author = "Jeanne Lusher and Meera Chitlur",

year = "2006",

month = nov,

doi = "10.1586/14750708.3.6.699",

language = "English",

volume = "3",

pages = "699--708",

journal = "Therapy",

issn = "1475-0708",

number = "6",

}

TY - JOUR

T1 - Kogenate® FS

T2 - Antihemophilic factor rFVIII-FS

AU - Lusher, Jeanne

AU - Chitlur, Meera

PY - 2006/11

Y1 - 2006/11

N2 - Characterization of the factor VIII (FVIII gene and expression of factor VIII through recombinant technology paved the way for the availability of recombinant factor VIII (rFVIII) for intravenous infusion, a significant breakthrough in the treatment of hemophilia A. Kogenate® FS(rFVIII-FS) is a native, full-length factor VIII molecule, produced from a baby hamster kidney cell line, purified and formulated without the addition of albumin, and stabilized with sucrose. Licensed in the USA and the EU in 2000, the hemostatic efficacy and safety (low rate of adverse events, viral safety and low incidence of inhibitors) have been consistently demonstrated through clinical trials and postmarketing studies. Accumulated evidence supports the use of rFVIII-FS for on-demand and prophylaxis treatment regimens, continuous infusion for surgeries or severe bleeding episodes, and immune tolerance induction for treatment of persistent inhibitors.

AB - Characterization of the factor VIII (FVIII gene and expression of factor VIII through recombinant technology paved the way for the availability of recombinant factor VIII (rFVIII) for intravenous infusion, a significant breakthrough in the treatment of hemophilia A. Kogenate® FS(rFVIII-FS) is a native, full-length factor VIII molecule, produced from a baby hamster kidney cell line, purified and formulated without the addition of albumin, and stabilized with sucrose. Licensed in the USA and the EU in 2000, the hemostatic efficacy and safety (low rate of adverse events, viral safety and low incidence of inhibitors) have been consistently demonstrated through clinical trials and postmarketing studies. Accumulated evidence supports the use of rFVIII-FS for on-demand and prophylaxis treatment regimens, continuous infusion for surgeries or severe bleeding episodes, and immune tolerance induction for treatment of persistent inhibitors.

KW - Factor VIII

KW - Hemophilia A

KW - Kogenate® FS

KW - Recombinant factor VIII

KW - Sucrose-formulated

UR - http://www.scopus.com/inward/record.url?scp=33845434377&partnerID=8YFLogxK

U2 - 10.1586/14750708.3.6.699

DO - 10.1586/14750708.3.6.699

M3 - Article

AN - SCOPUS:33845434377

SN - 1475-0708

VL - 3

SP - 699

EP - 708

JO - Therapy

JF - Therapy

IS - 6

ER -

Kogenate® FS: Antihemophilic factor rFVIII-FS

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this